Too young to fail: a case report on the effectiveness of tocilizumab for paediatric systemic sclerosis-associated interstitial lung disease

Scand J Rheumatol. 2021 Nov;50(6):491-492. doi: 10.1080/03009742.2021.1881154. Epub 2021 Mar 17.

Authors

V Maniscalco¹, E Marrani¹, E Rossi², I Maccora¹, M V Mastrolia¹, G Simonini^{2

3

4}

Affiliations

¹ Rheumatology Unit, Meyer Children's University Hospital, Pediatric Residency, University of Florence, Florence, Italy.
² Department of Imaging, Meyer Children's University Hospital, Florence, Italy.
³ Rheumatology Unit, Meyer Children's University Hospital, Florence, Italy.
⁴ NEUROFARBA Department, University of Florence, Florence, Italy.

PMID: 33729083
DOI: 10.1080/03009742.2021.1881154

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / therapeutic use
Child
Humans
Lung Diseases, Interstitial* / drug therapy
Lung Diseases, Interstitial* / etiology
Scleroderma, Systemic* / complications
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab